According to the Zhitong Finance App, Zejing Pharmaceutical (688266.SH) disclosed its 2026 semi-annual report. During the reporting period, the company achieved revenue of 1.05 billion yuan, an increase of 220.88%; net profit attributable to shareholders of listed companies was 640 million yuan, which turned a year-on-year loss into a profit; deducted non-net profit of 617 million yuan, which turned a year-on-year loss into a profit; and basic earnings per share were 2.42 yuan.

The sharp increase in revenue was mainly due to the company's confirmed revenue of 662 million yuan in product technology licensing during the reporting period, while sales revenue for commercial products increased by 44.30% compared to the same period last year.

Net assets attributable to shareholders of listed companies increased by 59.24% over the same period last year. The company achieved semi-annual profit for the first time since its establishment, driving a corresponding increase in net assets. At the same time, earnings per share and weighted average return on net assets before and after deducting non-recurring profit and loss all changed from negative to positive.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.